{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:29:47Z","timestamp":1771266587938,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["961802"],"award-info":[{"award-number":["961802"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["973128"],"award-info":[{"award-number":["973128"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Circulating tumor cells (CTCs) have recently been considered as new prognostic and diagnostic markers for various human cancers; however, their significance in epithelial ovarian cancer (EOC) remains to be elucidated. In this study, using quantitative real-time PCR, we evaluated the expression of <jats:italic>EPCAM<\/jats:italic>, <jats:italic>MUC1<\/jats:italic>, <jats:italic>CEA<\/jats:italic>, <jats:italic>HE4<\/jats:italic> and <jats:italic>CA125<\/jats:italic> mRNAs, as putative markers of CTCs, in the blood of 51 EOC patients before and\/or after adjuvant chemotherapy. Our results demonstrated that, before chemotherapy, the expression of <jats:italic>EPCAM<\/jats:italic>, <jats:italic>MUC1<\/jats:italic>, <jats:italic>CEA<\/jats:italic> and <jats:italic>HE4<\/jats:italic> mRNAs were correlated to each other. <jats:italic>CEA<\/jats:italic> expression was correlated with tumor stage (r\u2009=\u20090.594, <jats:italic>p<\/jats:italic>\u2009=\u20090.000) before chemotherapy, whereas its expression after chemotherapy was correlated with serum levels of CA125 antigen (r\u2009=\u20090.658, <jats:italic>p<\/jats:italic>\u2009=\u20090.000). <jats:italic>HE4<\/jats:italic> mRNA showed the highest sensitivity both before and after chemotherapy (82.98% and 85.19%, respectively) and the persistence of this marker after chemotherapy was associated with advanced disease stage. The expression of <jats:italic>CA125<\/jats:italic> mRNA had negative correlation with the other markers and with tumor stage and therapy response (evaluated by the measurement of serum CA125 antigen). Collectively, our results indicated a better clinical significance of tumor-specific markers (<jats:italic>CEA<\/jats:italic> and <jats:italic>HE4<\/jats:italic> mRNAs) compared to epithelial-specific markers (<jats:italic>EPCAM<\/jats:italic> and <jats:italic>MUC1<\/jats:italic> mRNAs).<\/jats:p>","DOI":"10.1038\/s41598-021-88780-w","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T10:06:23Z","timestamp":1621332383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical significance of circulating tumor cell related markers in patients with epithelial ovarian cancer before and after adjuvant chemotherapy"],"prefix":"10.1038","volume":"11","author":[{"given":"Meysam","family":"Yousefi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Rajaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahideh","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somayeh","family":"Bolandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malihe","family":"Hasanzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Pasdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"88780_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 67, 7\u201330. https:\/\/doi.org\/10.3322\/caac.21387 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"88780_CR2","unstructured":"Cancer Stat Facts: Ovarian Cancer <https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html> (2020)."},{"key":"88780_CR3","doi-asserted-by":"publisher","first-page":"C444","DOI":"10.1152\/ajpcell.00188.2015","volume":"309","author":"TL Yeung","year":"2015","unstructured":"Yeung, T. L. et al. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis. Am. J. Physiol. Cell Physiol. 309, C444-456. https:\/\/doi.org\/10.1152\/ajpcell.00188.2015 (2015).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"88780_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.201303698","volume":"7","author":"SA Joosse","year":"2015","unstructured":"Joosse, S. A., Gorges, T. M. & Pantel, K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol. Med. 7, 1\u201311. https:\/\/doi.org\/10.15252\/emmm.201303698 (2015).","journal-title":"EMBO Mol. Med."},{"key":"88780_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-3-319-22909-6_10","volume":"882","author":"C Paoletti","year":"2016","unstructured":"Paoletti, C. & Hayes, D. F. Circulating tumor cells. Adv. Exp. Med. Biol. 882, 235\u2013258. https:\/\/doi.org\/10.1007\/978-3-319-22909-6_10 (2016).","journal-title":"Adv. Exp. Med. Biol."},{"key":"88780_CR6","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781\u2013791. https:\/\/doi.org\/10.1056\/NEJMoa040766 (2004).","journal-title":"N. Engl. J. Med."},{"key":"88780_CR7","doi-asserted-by":"publisher","first-page":"617421","DOI":"10.1155\/2010\/617421","volume":"2010","author":"MC Miller","year":"2010","unstructured":"Miller, M. C., Doyle, G. V. & Terstappen, L. W. Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J. Oncol. 2010, 617421. https:\/\/doi.org\/10.1155\/2010\/617421 (2010).","journal-title":"J. Oncol."},{"key":"88780_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13402-019-00470-y","volume":"43","author":"M Yousefi","year":"2020","unstructured":"Yousefi, M. et al. Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer. Cell. Oncol. (Dordr.) 43, 31\u201349. https:\/\/doi.org\/10.1007\/s13402-019-00470-y (2020).","journal-title":"Cell. Oncol. (Dordr.)"},{"key":"88780_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1373\/clinchem.2012.188557","volume":"59","author":"C Gasch","year":"2013","unstructured":"Gasch, C. et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS\/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin. Chem. 59, 252\u2013260. https:\/\/doi.org\/10.1373\/clinchem.2012.188557 (2013).","journal-title":"Clin. Chem."},{"key":"88780_CR10","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/nm.3391","volume":"19","author":"L Wan","year":"2013","unstructured":"Wan, L., Pantel, K. & Kang, Y. Tumor metastasis: moving new biological insights into the clinic. Nat. Med. 19, 1450\u20131464. https:\/\/doi.org\/10.1038\/nm.3391 (2013).","journal-title":"Nat. Med."},{"key":"88780_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1056\/NEJMoa0800668","volume":"359","author":"S Maheswaran","year":"2008","unstructured":"Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366\u2013377. https:\/\/doi.org\/10.1056\/NEJMoa0800668 (2008).","journal-title":"N. Engl. J. Med."},{"key":"88780_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10549-010-1163-x","volume":"124","author":"T Fehm","year":"2010","unstructured":"Fehm, T. et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res. Treat. 124, 403\u2013412. https:\/\/doi.org\/10.1007\/s10549-010-1163-x (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"88780_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13402-018-0376-6","volume":"41","author":"M Yousefi","year":"2018","unstructured":"Yousefi, M. et al. Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis. Cell. Oncol. (Dordr.) 41, 123\u2013140. https:\/\/doi.org\/10.1007\/s13402-018-0376-6 (2018).","journal-title":"Cell. Oncol. (Dordr.)"},{"key":"88780_CR14","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/s1470-2045(06)70939-1","volume":"7","author":"DS Tan","year":"2006","unstructured":"Tan, D. S., Agarwal, R. & Kaye, S. B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 7, 925\u2013934. https:\/\/doi.org\/10.1016\/s1470-2045(06)70939-1 (2006).","journal-title":"Lancet Oncol."},{"key":"88780_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-020-00513-9","author":"M Yousefi","year":"2020","unstructured":"Yousefi, M. et al. Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles. Cell. Oncol. (Dordr.) https:\/\/doi.org\/10.1007\/s13402-020-00513-9 (2020).","journal-title":"Cell. Oncol. (Dordr.)"},{"key":"88780_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","volume":"26","author":"S Pradeep","year":"2014","unstructured":"Pradeep, S. et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26, 77\u201391. https:\/\/doi.org\/10.1016\/j.ccr.2014.05.002 (2014).","journal-title":"Cancer Cell"},{"key":"88780_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.trsl.2016.03.016","volume":"175","author":"LG Coffman","year":"2016","unstructured":"Coffman, L. G. et al. New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination. Transl. Res. J. Lab. Clin. Med. 175, 92-102.e102. https:\/\/doi.org\/10.1016\/j.trsl.2016.03.016 (2016).","journal-title":"Transl. Res. J. Lab. Clin. Med."},{"key":"88780_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13048-015-0168-9","volume":"8","author":"L Cui","year":"2015","unstructured":"Cui, L., Kwong, J. & Wang, C. C. Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis. J. Ovarian Res. 8, 38. https:\/\/doi.org\/10.1186\/s13048-015-0168-9 (2015).","journal-title":"J. Ovarian Res."},{"key":"88780_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1097\/IGC.0b013e318216cb91","volume":"21","author":"B Aktas","year":"2011","unstructured":"Aktas, B., Kasimir-Bauer, S., Heubner, M., Kimmig, R. & Wimberger, P. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 21, 822\u2013830. https:\/\/doi.org\/10.1097\/IGC.0b013e318216cb91 (2011).","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"88780_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2012.09.021","volume":"128","author":"E Obermayr","year":"2013","unstructured":"Obermayr, E. et al. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance\u2014a study of the OVCAD consortium. Gynecol. Oncol. 128, 15\u201321. https:\/\/doi.org\/10.1016\/j.ygyno.2012.09.021 (2013).","journal-title":"Gynecol. Oncol."},{"key":"88780_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/1354750x.2013.865275","volume":"19","author":"M Sang","year":"2014","unstructured":"Sang, M. et al. Multiple MAGE-A genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer. Biomark. Biochem. Indic. Expo. Response Susceptibility Chem. 19, 34\u201342. https:\/\/doi.org\/10.3109\/1354750x.2013.865275 (2014).","journal-title":"Biomark. Biochem. Indic. Expo. Response Susceptibility Chem."},{"key":"88780_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ygyno.2017.02.042","volume":"145","author":"M Lee","year":"2017","unstructured":"Lee, M. et al. Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer. Gynecol. Oncol. 145, 361\u2013365. https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.042 (2017).","journal-title":"Gynecol. Oncol."},{"key":"88780_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ygyno.2008.09.021","volume":"112","author":"T Fan","year":"2009","unstructured":"Fan, T., Zhao, Q., Chen, J. J., Chen, W. T. & Pearl, M. L. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol. Oncol. 112, 185\u2013191. https:\/\/doi.org\/10.1016\/j.ygyno.2008.09.021 (2009).","journal-title":"Gynecol. Oncol."},{"key":"88780_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","volume":"122","author":"A Poveda","year":"2011","unstructured":"Poveda, A. et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer. Gynecol. Oncol. 122, 567\u2013572. https:\/\/doi.org\/10.1016\/j.ygyno.2011.05.028 (2011).","journal-title":"Gynecol. Oncol."},{"key":"88780_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ygyno.2014.06.013","volume":"134","author":"ML Pearl","year":"2014","unstructured":"Pearl, M. L. et al. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer. Gynecol. Oncol. 134, 581\u2013590. https:\/\/doi.org\/10.1016\/j.ygyno.2014.06.013 (2014).","journal-title":"Gynecol. Oncol."},{"key":"88780_CR26","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1159\/000492521","volume":"48","author":"X Zhang","year":"2018","unstructured":"Zhang, X. et al. Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 48, 1983\u20131994. https:\/\/doi.org\/10.1159\/000492521 (2018).","journal-title":"Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol."},{"key":"88780_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-019-0735-4","volume":"12","author":"P Bank\u00f3","year":"2019","unstructured":"Bank\u00f3, P. et al. Technologies for circulating tumor cell separation from whole blood. J. Hematol. Oncol. 12, 48. https:\/\/doi.org\/10.1186\/s13045-019-0735-4 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"88780_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","volume":"19","author":"SG Silverberg","year":"2000","unstructured":"Silverberg, S. G. Histopathologic grading of ovarian carcinoma: a review and proposal. Int. J. Gynecol. Pathol. Off. J. Int. Soc. Gynecol. Pathol. 19, 7\u201315. https:\/\/doi.org\/10.1097\/00004347-200001000-00003 (2000).","journal-title":"Int. J. Gynecol. Pathol. Off. J. Int. Soc. Gynecol. Pathol."},{"key":"88780_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijgo.2008.12.015","volume":"105","author":"FIGO Committee on Gynecologic Oncology","year":"2009","unstructured":"FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int. J. Gynaecol. Obstetr. Off. Organ Int. Feder. Gynaecol. Obstetr. 105, 3\u20134. https:\/\/doi.org\/10.1016\/j.ijgo.2008.12.015 (2009).","journal-title":"Int. J. Gynaecol. Obstetr. Off. Organ Int. Feder. Gynaecol. Obstetr."},{"key":"88780_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1210\/edrv.22.2.0422","volume":"22","author":"N Auersperg","year":"2001","unstructured":"Auersperg, N., Wong, A. S., Choi, K. C., Kang, S. K. & Leung, P. C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22, 255\u2013288. https:\/\/doi.org\/10.1210\/edrv.22.2.0422 (2001).","journal-title":"Endocr. Rev."},{"key":"88780_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/AOG.0000000000001196","volume":"127","author":"JJ Lin","year":"2016","unstructured":"Lin, J. J., Egorova, N., Franco, R., Prasad-Hayes, M. & Bickell, N. A. Ovarian cancer treatment and survival trends among women older than 65 years of age in the United States, 1995\u20132008. Obstet. Gynecol. 127, 81\u201389. https:\/\/doi.org\/10.1097\/AOG.0000000000001196 (2016).","journal-title":"Obstet. Gynecol."},{"key":"88780_CR32","doi-asserted-by":"publisher","first-page":"475983","DOI":"10.1155\/2011\/475983","volume":"2011","author":"BJ Rein","year":"2011","unstructured":"Rein, B. J. et al. Potential markers for detection and monitoring of ovarian cancer. J. Oncol. 2011, 475983. https:\/\/doi.org\/10.1155\/2011\/475983 (2011).","journal-title":"J. Oncol."},{"key":"88780_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1757-2215-2-13","volume":"2","author":"D Gupta","year":"2009","unstructured":"Gupta, D. & Lis, C. G. Role of CA125 in predicting ovarian cancer survival\u2014a review of the epidemiological literature. J. Ovarian Res. 2, 13. https:\/\/doi.org\/10.1186\/1757-2215-2-13 (2009).","journal-title":"J. Ovarian Res."},{"key":"88780_CR34","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ygyno.2006.09.028","volume":"104","author":"EV Hogdall","year":"2007","unstructured":"Hogdall, E. V. et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish \u201cMALOVA\u201d Ovarian Cancer Study. Gynecol. Oncol. 104, 508\u2013515. https:\/\/doi.org\/10.1016\/j.ygyno.2006.09.028 (2007).","journal-title":"Gynecol. Oncol."},{"key":"88780_CR35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/1096-9098(200012)75:4<264::aid-jso7>3.0.co;2-q","volume":"75","author":"P Buamah","year":"2000","unstructured":"Buamah, P. Benign conditions associated with raised serum CA-125 concentration. J. Surg. Oncol. 75, 264\u2013265. https:\/\/doi.org\/10.1002\/1096-9098(200012)75:4%3c264::aid-jso7%3e3.0.co;2-q (2000).","journal-title":"J. Surg. Oncol."},{"key":"88780_CR36","doi-asserted-by":"publisher","first-page":"206s","DOI":"10.1200\/jco.2003.02.955","volume":"21","author":"SJ Skates","year":"2003","unstructured":"Skates, S. J. et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 21, 206s\u2013210s. https:\/\/doi.org\/10.1200\/jco.2003.02.955 (2003).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"88780_CR37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ajog.2008.04.009","volume":"199","author":"V Nossov","year":"2008","unstructured":"Nossov, V. et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?. Am. J. Obstetr. Gynecol. 199, 215\u2013223. https:\/\/doi.org\/10.1016\/j.ajog.2008.04.009 (2008).","journal-title":"Am. J. Obstetr. Gynecol."},{"key":"88780_CR38","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1159\/000492521","volume":"48","author":"X Zhang","year":"2018","unstructured":"Zhang, X. et al. Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker. Cell. Physiol. Biochem. 48, 1983\u20131994. https:\/\/doi.org\/10.1159\/000492521 (2018).","journal-title":"Cell. Physiol. Biochem."},{"key":"88780_CR39","first-page":"3695","volume":"63","author":"I Hellstrom","year":"2003","unstructured":"Hellstrom, I. et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63, 3695\u20133700 (2003).","journal-title":"Cancer Res."},{"key":"88780_CR40","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.can-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin, R. et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 65, 2162\u20132169. https:\/\/doi.org\/10.1158\/0008-5472.can-04-3924 (2005).","journal-title":"Cancer Res."},{"key":"88780_CR41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13048-019-0503-7","volume":"12","author":"V Dochez","year":"2019","unstructured":"Dochez, V. et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J. Ovarian Res. 12, 28. https:\/\/doi.org\/10.1186\/s13048-019-0503-7 (2019).","journal-title":"J. Ovarian Res."},{"key":"88780_CR42","doi-asserted-by":"publisher","first-page":"7522","DOI":"10.18632\/oncotarget.23943","volume":"9","author":"Y-X Guo","year":"2018","unstructured":"Guo, Y.-X. et al. Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer. Oncotarget 9, 7522\u20137533. https:\/\/doi.org\/10.18632\/oncotarget.23943 (2018).","journal-title":"Oncotarget"},{"key":"88780_CR43","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1016\/j.febslet.2009.10.036","volume":"583","author":"T Maier","year":"2009","unstructured":"Maier, T., G\u00fcell, M. & Serrano, L. Correlation of mRNA and protein in complex biological samples. FEBS Lett. 583, 3966\u20133973. https:\/\/doi.org\/10.1016\/j.febslet.2009.10.036 (2009).","journal-title":"FEBS Lett."},{"key":"88780_CR44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.clinbiochem.2004.05.009","volume":"37","author":"V Barak","year":"2004","unstructured":"Barak, V., Goike, H., Panaretakis, K. W. & Einarsson, R. Clinical utility of cytokeratins as tumor markers. Clin. Biochem. 37, 529\u2013540. https:\/\/doi.org\/10.1016\/j.clinbiochem.2004.05.009 (2004).","journal-title":"Clin. Biochem."},{"key":"88780_CR45","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.bjc.6603494","volume":"96","author":"PA Baeuerle","year":"2007","unstructured":"Baeuerle, P. A. & Gires, O. EpCAM (CD326) finding its role in cancer. Br. J. Cancer 96, 417\u2013423. https:\/\/doi.org\/10.1038\/sj.bjc.6603494 (2007).","journal-title":"Br. J. Cancer"},{"key":"88780_CR46","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cocis.2005.11.001","volume":"11","author":"R Bansil","year":"2006","unstructured":"Bansil, R. & Turner, B. S. Mucin structure, aggregation, physiological functions and biomedical applications. Curr. Opin. Colloid Interface Sci. 11, 164\u2013170. https:\/\/doi.org\/10.1016\/j.cocis.2005.11.001 (2006).","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"88780_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4161\/cam.23131","volume":"7","author":"TM Horm","year":"2013","unstructured":"Horm, T. M. & Schroeder, J. A. MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adhes. Migr. 7, 187\u2013198. https:\/\/doi.org\/10.4161\/cam.23131 (2013).","journal-title":"Cell Adhes. Migr."},{"key":"88780_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bios.2019.01.015","volume":"130","author":"M Yousefi","year":"2019","unstructured":"Yousefi, M. et al. Aptasensors as a new sensing technology developed for the detection of MUC1 mucin: a review. Biosens. Bioelectron. 130, 1\u201319. https:\/\/doi.org\/10.1016\/j.bios.2019.01.015 (2019).","journal-title":"Biosens. Bioelectron."},{"key":"88780_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1006\/scbi.1998.0119","volume":"9","author":"S Hammarstrom","year":"1999","unstructured":"Hammarstrom, S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 9, 67\u201381. https:\/\/doi.org\/10.1006\/scbi.1998.0119 (1999).","journal-title":"Semin. Cancer Biol."},{"key":"88780_CR50","first-page":"3419","volume":"60","author":"C Ordo\u00f1ez","year":"2000","unstructured":"Ordo\u00f1ez, C., Screaton, R. A., Ilantzis, C. & Stanners, C. P. Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res. 60, 3419 (2000).","journal-title":"Cancer Res."},{"key":"88780_CR51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1349-7006.2008.01022.x","volume":"100","author":"K Yamashita","year":"2009","unstructured":"Yamashita, K. & Watanabe, M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci. 100, 195\u2013199. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.01022.x (2009).","journal-title":"Cancer Sci."},{"key":"88780_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/1096-9098(200007)74:3<185::aid-jso4>3.0.co;2-0","volume":"74","author":"DY Kim","year":"2000","unstructured":"Kim, D. Y. et al. Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J. Surg. Oncol. 74, 185\u2013192. https:\/\/doi.org\/10.1002\/1096-9098(200007)74:3%3c185::aid-jso4%3e3.0.co;2-0 (2000).","journal-title":"J. Surg. Oncol."},{"key":"88780_CR53","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/00313020802197889","volume":"40","author":"EVS H\u00f8gdall","year":"2008","unstructured":"H\u00f8gdall, E. V. S. et al. Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish \u2019MALOVA\u2019ovarian cancer study. Pathology 40, 487\u2013492. https:\/\/doi.org\/10.1080\/00313020802197889 (2008).","journal-title":"Pathology"},{"key":"88780_CR54","first-page":"A4331","volume":"58","author":"SS Sorensen","year":"2011","unstructured":"Sorensen, S. S. & Mosgaard, B. J. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan. Med. Bull. 58, A4331 (2011).","journal-title":"Dan. Med. Bull."},{"key":"88780_CR55","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1186\/s12885-018-4987-0","volume":"18","author":"P Yu","year":"2018","unstructured":"Yu, P. et al. The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients. BMC Cancer 18, 1076. https:\/\/doi.org\/10.1186\/s12885-018-4987-0 (2018).","journal-title":"BMC Cancer"},{"key":"88780_CR56","first-page":"1883","volume":"23","author":"A Stathopoulou","year":"2003","unstructured":"Stathopoulou, A. et al. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res. 23, 1883\u20131890 (2003).","journal-title":"Anticancer Res."},{"key":"88780_CR57","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s00595-004-2978-z","volume":"35","author":"M Ikeguchi","year":"2005","unstructured":"Ikeguchi, M. & Kaibara, N. Detection of circulating cancer cells after a gastrectomy for gastric cancer. Surg. Today 35, 436\u2013441. https:\/\/doi.org\/10.1007\/s00595-004-2978-z (2005).","journal-title":"Surg. Today"},{"key":"88780_CR58","first-page":"2239","volume":"33","author":"M Pesta","year":"2013","unstructured":"Pesta, M., Fichtl, J., Kulda, V., Topolcan, O. & Treska, V. Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Anticancer Res. 33, 2239\u20132243 (2013).","journal-title":"Anticancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88780-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88780-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88780-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T08:17:03Z","timestamp":1670055423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88780-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88780"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88780-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"4 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10524"}}